England is reopening its Cancer Drugs Fund with a crafty solution to rein in the overspending that blighted its predecessor: make drugmakers pay.
Under new rules, if the fund exceeds its 340 million-pound ($450 million) budget -- as it’s done in the past, overshooting by 37 percent in the final year before the revamp -- pharmaceutical manufacturers will pick up the tab. And there’s no cap on that bill.
